Moore KN et al. |
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. |
2018 |
Gynecol. Oncol. |
pmid:30093227
|
Wang L et al. |
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. |
2018 |
Cancer Sci. |
pmid:30076657
|
Andreev J et al. |
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. |
2017 |
Mol. Cancer Ther. |
pmid:28108597
|
Schönfeld K et al. |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. |
2017 |
J Hematol Oncol |
pmid:28077160
|
Moore KN et al. |
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. |
2017 |
J. Clin. Oncol. |
pmid:28029313
|
Lynce F et al. |
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. |
2017 |
Oncologist |
pmid:28314836
|
Janjigian YY and Braghiroli MI |
Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. |
2017 |
Surg. Oncol. Clin. N. Am. |
pmid:28279471
|
Socinski MA et al. |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. |
2017 |
Clin Lung Cancer |
pmid:28341109
|
Carvajal-Hausdorf DE et al. |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. |
2017 |
Gynecol. Oncol. |
pmid:28196634
|
Perez EA et al. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
2017 |
J. Clin. Oncol. |
pmid:28056202
|